Photo by cdc from unsplash
Röth and colleagues present results of a phase 3 trial of the C1s classical complement pathway inhibitor sutimlimab for the treatment of patients with cold agglutinin disease (CAD) who did… Click to show full abstract
Röth and colleagues present results of a phase 3 trial of the C1s classical complement pathway inhibitor sutimlimab for the treatment of patients with cold agglutinin disease (CAD) who did not receive a transfusion within the previous 6 months. In a randomized placebocontrolled study of 41 patients, 73% of patients treated with sutimlimab required no transfusion or additional therapy, and treatment increased mean hemoglobin and fatigue scores, as compared to only 15% in the placebo arm. This supports sutimlimab as an important new agent for the treatment of CAD.
Journal Title: Blood
Year Published: 2022
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!